REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2015--
Heron Therapeutics, Inc. (NASDAQ:HRTX), announced today that Barry D.
Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will
participate in the following conferences in November 2015:
Brean Capital 2015 Healthcare Conference in New York, NY. Monday,
November 16, 2015
Jefferies Autumn 2015 Global Healthcare Conference in London.
Presentation: Wednesday, November 18, 2015 at 4:00 p.m. GMT (8:00 a.m.
A live webcast of these presentations will be available on Heron’s
website at www.herontx.com
in the Investors section. Replays will be archived on the site for 90
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving
the lives of patients by developing best-in-class medicines that address
major unmet medical needs. Heron is developing novel, patient-focused
solutions that apply its innovative science and technologies to
already-approved pharmacological agents. Heron’s goal is to build on
therapeutics with well-known pharmacology by improving their
tolerability and efficacy as well as broadening their potential field of
use. Heron is currently developing four pharmaceutical products for
patients suffering from cancer or pain.
SUSTOL® (granisetron) Injection, extended release is being
developed for the prevention of both acute and delayed
chemotherapy-induced nausea and vomiting (CINV) associated with
moderately emetogenic chemotherapy (MEC) or highly emetogenic
chemotherapy (HEC). CINV is one of the most debilitating side effects of
chemotherapy and is a leading cause of premature discontinuation of
cancer treatment. Heron recently reported positive, top-line results
from its Phase 3 MAGIC study for SUSTOL for the prevention of delayed
CINV following HEC regimens. SUSTOL is not presently approved by any
regulatory authority. In July 2015, Heron resubmitted its New Drug
Application (NDA) for SUSTOL to the U.S. Food and Drug Administration
(FDA), and the FDA has assigned a Prescription Drug User Fee Act (PDUFA)
goal date of January 17, 2016. HTX-019, also being developed for the
prevention of CINV, has the potential to become the first polysorbate
80-free, intravenous formulation of aprepitant, a neurokinin-1 (NK1)
receptor antagonist. Heron intends to file an NDA for HTX-019 using the
505(b)(2) regulatory pathway in the second half of 2016. HTX-011 is
Heron’s long-acting formulation of the local anesthetic bupivacaine in a
fixed-dose combination with the anti-inflammatory meloxicam. In
September 2015, Heron reported positive, top-line results from a Phase 2
study of HTX-011 in patients undergoing bunionectomy. In this study,
HTX-011 significantly reduced pain intensity and the need for opioid
rescue medications. HTX-011 is the subject of a broad-based development
program designed to target the many patients undergoing a wide range of
surgeries who experience significant post-operative pain. HTX-003, a
long-acting formulation of buprenorphine, is being developed for the
potential management of chronic pain and opioid addiction.
All of Heron’s product candidates utilize Heron’s innovative science and
technology platforms, including its proprietary Biochronomer®
drug delivery technology, which can deliver therapeutic levels of a wide
range of otherwise short-acting pharmacological agents over a period of
days to weeks with a single injection.
For more information, visit www.herontx.com.
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, those associated with: whether the U.S. Food and
Drug Administration (FDA) approves the SUSTOL NDA as submitted or
supports as broad of a labeled indication for SUSTOL as requested, the
progress in the research and development of HTX-019, HTX-011, HTX-003
and our other programs, including the timing of preclinical, clinical,
and manufacturing activities, safety and efficacy results from our
studies that may not justify the pursuit of further development of our
product candidates, the launch and acceptance of SUSTOL and new products
generally, our financial position and our ability to raise additional
capital to fund operations, if necessary, or to pursue additional
business opportunities, strategic business alliances we may pursue or
the potential acquisition of products or technologies, and our ability
to grow our organization to sustain the commercial launch for SUSTOL,
and other risks and uncertainties identified in the Company's filings
with the Securities and Exchange Commission. Forward-looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151110005551/en/
Source: Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Investor Relations Contact:
Associate Director, Investor Relations
Barry D. Quart, Pharm. D., 650-366-2626